The new Affymax (NASDAQ: AFFY) is building upon its proven discovery platform and extensive pharmaceutical experience to build a pipeline of peptide drugs to treat cancer and immune-mediated diseases. The powerful combination of broad management experience, clinical development know-how, a proven drug discovery engine and strong intellectual property, positions Affymax as a preeminent drug discovery and development company. The Company has been a pioneer in chemistry and high throughput screening technologies that enable faster and more efficient processes for drug discovery by integrating proprietary chemistries, innovative molecular biology techniques, sophisticated software and instrumentation technology.

Financials

Date Type Amount Investors Valuation
04/11/06 Series E 10M Apax Partners, Bear Stearns Health Innoventures, Bessemer Venture Partners, Diamond Capital, Jafco Ventures, Merlin BioMed Group, MPM Capital, Sprout Group, Ciba Geigy, Dow Chemical, InterHealth, Intuit, Marion Merrill Dow, Maxwell Communications Unknown

People

Kay Slocum (SVP Human Resources)

Christopher Dammann (VP Business Development)

R. Douglas (Board Member)

Peter Young (VP Research)

Douglas Cole (VP Development)

View more details about all 37 people at Affymax